Asian Journal of Dental Sciences

Diabetes mellitus, a chronic metabolic disorder characterized by impaired glucose metabolism due to insulin deficiency or resistance, is increasingly recognized for its bidirectional relationship with periodontal disease. Both Type 1 and Type 2 diabetes are associated with elevated risks of developing periodontitis, a prevalent inflammatory condition affecting the tooth-supporting structures. Poor glycemic control amplifies host immune responses, leading to heightened inflammation, altered subgingival microbiota, impaired tissue healing, and disrupted bone metabolism. Experimental and clinical studies highlight the roles of hyperglycemia, pro-inflammatory cytokines, and advanced glycation end products (AGEs) interacting with their receptor (RAGE) in exacerbating periodontal breakdown. Furthermore, periodontitis-induced systemic inflammation can worsen insulin resistance and glycemic control, forming a cyclical interaction that complicates disease management. Evidence suggests that periodontal therapy can positively influence glycemic outcomes, emphasizing the importance of integrated care. Understanding this complex interrelationship is vital for optimizing therapeutic approaches and improving outcomes in patients affected by both conditions.